Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2021-03-29 AGM Information
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ)
AGM Information Classification · 100% confidence The document is titled "Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ)" which translates to "Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)". It details the date (May 4, 2021), the procedure (postal voting due to COVID-19), registration requirements, and presents a detailed agenda (Förslag till dagordning) covering items typical for an AGM, such as election of the chairman, approval of the annual report (item 6), dividend decisions (item 8), remuneration reports (item 13), and proposals for changes to the articles of association (item 14) and incentive programs (item 15). This content is characteristic of a formal notice and materials related to an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2021-03-29 Swedish
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled 'Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)' and details the procedures for shareholders to participate via postal vote, the proposed agenda items (including election of directors, approval of reports, and remuneration), and specific dates related to the meeting (May 4, 2021). This content directly corresponds to the materials distributed to shareholders in advance of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information). The document length is substantial (49,539 chars), confirming it is the notice/material itself, not just a brief announcement of publication (RPA/RNS).
2021-03-29 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 95% confidence The document is a 'Bokslutskommuniké 2020' (Year-end Report 2020) for the company Sobi. It contains comprehensive financial tables (income statements, quarterly comparisons), detailed management commentary on business segments (Haematology, Immunology, Specialty Care), R&D updates, and sustainability information. As it provides substantive financial data and analysis for the full fiscal year, it is classified as an Interim/Quarterly Report (IR) in the context of financial reporting standards, as it serves as the primary financial disclosure document for the period. Q4 2020
2021-02-18 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is a 'Q4/FY 2020 report' for Sobi, containing detailed financial tables (revenue, EBITA, EPS), a CEO statement, a business review of operational segments (Haematology, Immunology, Specialty Care), and a financial review. It provides substantive financial data and analysis for the full fiscal year and the fourth quarter. It is not a short announcement (it is over 95,000 characters) and contains actual financial statements/data, thus qualifying as an Interim/Quarterly Report. Q4 2020
2021-02-18 English
Major Shareholding Notification 2021
Major Shareholding Notification Classification · 98% confidence The document details a change in shareholding percentage for a specific holder ('Fjärde AP-fonden') in an issuer ('Swedish Orphan Biovitrum AB (publ)'). It explicitly shows the 'Before the transaction' and 'After the transaction' share quantities and the resulting percentage (5.04%). This type of filing, which reports changes in significant share ownership crossing predefined thresholds (like 5%), directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2021-02-01 English
Sobi och Apellis redovisar positiva topline-resultat från fas 3-studien PEGASUS efter 48 veckors behandling med pegcetacoplan vid PNH
Regulatory Filings Classification · 95% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces positive topline results from a Phase 3 clinical trial (PEGASUS) for a drug (pegcetacoplan) used to treat PNH. It details efficacy and safety data from 48 weeks of treatment. This type of announcement, which releases key financial/clinical results immediately to the public, aligns best with an Earnings Release (ER) or, more broadly, a general regulatory announcement. Since it is a press release announcing clinical trial results rather than a formal quarterly/annual financial report (10-K or IR), and it is not a transcript (CT) or a presentation (IP), it functions as an initial release of performance data. Given the options, 'ER' (Earnings Release) is the closest fit for a major announcement of clinical/performance milestones, although 'RNS' (Regulatory Filings) is also plausible as a general announcement. However, the content is focused on results, making 'ER' more specific than the general fallback 'RNS'. The document length is substantial (9884 chars), indicating it is the full announcement, not just a brief notice of publication (RPA).
2020-12-10 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.